Chinese biotechs once aspired to launching their products in the US and listing on Nasdaq as their ultimate achievements, but now many are turning more attention to their home turf and the Shanghai Stock Market as the preferred listing venue to raise funds.
Refocus On China: Ark Bio Evolves As It Plans Shanghai Listing
Eyes R&D In Less Crowded Sectors
Shanghai-based Ark Biosciences has expanded its pipeline from the RSV-targeting drug ziresovir, licensed from Roche, to pediatric and fibrosis treatments, where there are largely untapped opportunities in China. In a strategy shift, the company is betting on the domestic market instead of going global.
